Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis
Background: Limited information exists on the healthcare resource utilization (HCRU) associated with real-world natalizumab used as a first-line (1L) versus later-line (2L+) treatment in multiple sclerosis (MS). Objectives: To describe natalizumab use in newly diagnosed MS patients treated as 1L or...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864251317949 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|